The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370 · cited 1×
“An important consideration for siRNA-mediated inhibition of gene expression is whether the observed effects are specific and not due to nonspecific “off target” effect”
BackgroundMicroRNA-Directed Cleavage of HOXB8 mRNA
Yekta, S., Shih, I.-H., & Bartel, D. P. (2004) · Science · doi:10.1126/science.1097434 · Cited by 1,702
Cleavage of Scarecrow-like mRNA Targets Directed by a Class of Arabidopsis miRNA
Llave, C., Xie, Z., Kasschau, K. D., & Carrington, J. C. (2002) · Science · doi:10.1126/science.1076311 · Cited by 1,627 · cited 1×
“Determination of in vivo mechanism of action To prove that the in vivo activity was due to siRNA-directed cleavage, we characterized specific mRNA cleavage products using a modified 5′-RACE (rapid amplification of cDNA ends) technique previously used to demonstrate microRNA (miRNA)-directed mRNA cleavage in plant”
MethodRNA interference targeting Fas protects mice from fulminant hepatitis
Song, E., Lee, S.-K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., & Lieberman, J. (2003) · Nature Medicine · doi:10.1038/nm828 · Cited by 1,110
Induction of an interferon response by RNAi vectors in mammalian cells
Bridge, A. J., Pebernard, S., Ducraux, A., Nicoulaz, A.-L., & Iggo, R. (2003) · Nature Genetics · doi:10.1038/ng1173 · Cited by 961
Novina, C. D., & Sharp, P. A. (2004) · Nature · doi:10.1038/430161a · Cited by 724
Reich, S. J., Fosnot, J., Kuroki, A. M., Tang, W., Yang, X., Maguire, A. M., Bennett, J., & Tolentino, M. J. (2003) · PubMed · Cited by 441
siRNA relieves chronic neuropathic pain
Dorn, G. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh044 · Cited by 381
Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells
Lorenz, C., Hadwiger, P., John, M., Vornlocher, H.-P., & Unverzagt, C. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.07.018 · Cited by 338
Self-citation
Cited by
Items 101–200 of 215
DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R. K., Rajeev, K. G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708285104 · Cited by 415
Self-citationRNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Targeted Quantum Dot Conjugates for siRNA Delivery
Derfus, A. M., Chen, A. A., Min, D.-H., Ruoslahti, E., & Bhatia, S. N. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060367e · Cited by 395
Materials for non-viral intracellular delivery of messenger RNA therapeutics
Kauffman, K. J., Webber, M. J., & Anderson, D. G. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.032 · Cited by 395
MicroRNAs in Disease and Potential Therapeutic Applications
Soifer, H. S., Rossi, J. J., & Sætrom, P. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300311 · Cited by 394
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
Controlling drug nanoparticle formation by rapid precipitation
D'Addio, S. M., & Prud'homme, R. K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.04.005 · Cited by 392
Gene therapy progress and prospects: non-viral gene therapy by systemic delivery
Li, S.-D., & Huang, L. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302838 · Cited by 391
The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing
Liu, X., Howard, K. A., Dong, M., Andersen, M. Ø., Rahbek, U. L., Johnsen, M. G., Hansen, O. C., Besenbacher, F., & Kjems, J. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.11.004 · Cited by 391
Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics
Ding, D., & Zhu, Q. (2018) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.12.036 · Cited by 386
Gleave, M. E., & Monia, B. P. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1631 · Cited by 384
RNA interference: From gene silencing to gene-specific therapeutics
Leung, R. K. M., & Whittaker, P. A. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.03.004 · Cited by 382
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
Toward MicroRNA–Based Therapeutics for Heart Disease: The Sense in Antisense
van Rooij, E., Marshall, W. S., & Olson, E. N. (2008) · Circulation Research · doi:10.1161/circresaha.108.183426 · Cited by 377
Bramsen, J. B., Laursen, M. B., Nielsen, A. F., Hansen, T. B., Bus, C., Langkjær, N., Babu, B. R., Højland, T., Abramov, M., Van Aerschot, A., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp106 · Cited by 369
GLI transcription factors: Mediators of oncogenic Hedgehog signalling
Kasper, M., Regl, G., Frischauf, A.-M., & Aberger, F. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.039 · Cited by 369
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium
Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V, Fisch, G., Dames, S., Löffler, K., Fechtner, M., Arnold, W., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302777 · Cited by 368
Lee, J., Lee, K., Moon, S. H., Lee, Y., Park, T. G., & Cheon, J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200805998 · Cited by 365
Zhang, R., Qin, X., Kong, F., Chen, P., & Pan, G. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1582730 · Cited by 363
Cell‐penetrating peptides: from molecular mechanisms to therapeutics
Morris, M. C., Deshayes, S., Heitz, F., & Divita, G. (2008) · Biology of the Cell · doi:10.1042/bc20070116 · Cited by 361
Activation of the mammalian immune system by siRNAs
Marques, J. T., & Williams, B. R. G. (2005) · Nature Biotechnology · doi:10.1038/nbt1161 · Cited by 358
Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J., & Crooke, R. M. (2006) · Circulation · doi:10.1161/circulationaha.105.606442 · Cited by 358
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo
Takeshita, F., Minakuchi, Y., Nagahara, S., Honma, K., Sasaki, H., Hirai, K., Teratani, T., Namatame, N., Yamamoto, Y., Hanai, K., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501753102 · Cited by 355
Lipoprotein metabolism and lipid management in chronic kidney disease
Kwan, B. C. H., Kronenberg, F., Beddhu, S., & Cheung, A. K. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006091006 · Cited by 354
Moschos, S. A., Jones, S. W., Perry, M. M., Williams, A. E., Erjefalt, J. S., Turner, J. J., Barnes, P. J., Sproat, B. S., Gait, M. J., & Lindsay, M. A. (2007) · Bioconjugate Chemistry · doi:10.1021/bc070077d · Cited by 350
de Boer, A. G., & Gaillard, P. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105237 · Cited by 348
A New Potent Secondary Amphipathic Cell–penetrating Peptide for siRNA Delivery Into Mammalian Cells
Crombez, L., Aldrian-Herrada, G., Konate, K., Nguyen, Q. N., McMaster, G. K., Brasseur, R., Heitz, F., & Divita, G. (2009) · Molecular Therapy · doi:10.1038/mt.2008.215 · Cited by 346
He, X.-X., Chang, Y., Meng, F.-Y., Wang, M.-Y., Xie, Q.-H., Tang, F., Li, P.-Y., Song, Y.-H., & Lin, J.-S. (2012) · Oncogene · doi:10.1038/onc.2011.500 · Cited by 339
Intercellular and systemic movement of RNA silencing signals
Melnyk, C. W., Molnar, A., & Baulcombe, D. C. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.274 · Cited by 338
siRNA Conjugate Delivery Systems
Jeong, J. H., Mok, H., Oh, Y.-K., & Park, T. G. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800278e · Cited by 338
High-Density Lipoproteins: Nature’s Multifunctional Nanoparticles
Kuai, R., Li, D., Chen, Y. E., Moon, J. J., & Schwendeman, A. (2016) · ACS Nano · doi:10.1021/acsnano.5b07522 · Cited by 338
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
RNA Interference: From Basic Research to Therapeutic Applications
Kurreck, J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802092 · Cited by 335
Therapeutic plasmid DNA versus siRNA delivery: Common and different tasks for synthetic carriers
Scholz, C., & Wagner, E. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.014 · Cited by 333
Non-viral vectors for RNA delivery
Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332
Lipid–Drug Conjugate for Enhancing Drug Delivery
Irby, D., Du, C., & Li, F. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01027 · Cited by 331
Taratula, O., Garbuzenko, O. B., Kirkpatrick, P., Pandya, I., Savla, R., Pozharov, V. P., He, H., & Minko, T. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.019 · Cited by 328
Matsumoto, S., Christie, R. J., Nishiyama, N., Miyata, K., Ishii, A., Oba, M., Koyama, H., Yamasaki, Y., & Kataoka, K. (2009) · Biomacromolecules · doi:10.1021/bm800985e · Cited by 327
Biological Gene Delivery Vehicles: Beyond Viral Vectors
Seow, Y., & Wood, M. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.41 · Cited by 327
The silent treatment: siRNAs as small molecule drugs
Dykxhoorn, D. M., Palliser, D., & Lieberman, J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302703 · Cited by 324
Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver
Akinc, A., Goldberg, M., Qin, J., Dorkin, J. R., Gamba-Vitalo, C., Maier, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Manoharan, M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.36 · Cited by 323
Self-citationEfficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol
Nishina, K., Unno, T., Uno, Y., Kubodera, T., Kanouchi, T., Mizusawa, H., & Yokota, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.14 · Cited by 312
Functional polarity is introduced by Dicer processing of short substrate RNAs
Rose, S. D. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki732 · Cited by 312
Efficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 309
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Biological Barriers to Therapy with Antisense and siRNA Oligonucleotides
Juliano, R., Bauman, J., Kang, H., & Ming, X. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900093r · Cited by 304
On the art of identifying effective and specific siRNAs
Pei, Y., & Tuschl, T. (2006) · Nature Methods · doi:10.1038/nmeth911 · Cited by 302
Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 Therapy
Zhou, J., Li, H., Li, S., Zaia, J., & Rossi, J. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.92 · Cited by 301
Deng, Y., Wang, C. C., Choy, K. W., Du, Q., Chen, J., Wang, Q., Li, L., Chung, T. K. H., & Tang, T. (2014) · Gene · doi:10.1016/j.gene.2013.12.019 · Cited by 301
Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application
Adachi, T., & Nakamura, Y. (2019) · Molecules · doi:10.3390/molecules24234229 · Cited by 300
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
Baumann, V., & Winkler, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.116 · Cited by 297
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 297
Nano-based delivery of RNAi in cancer therapy
Xin, Y., Huang, M., Guo, W. W., Huang, Q., Zhang, L. Z., & Jiang, G. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0683-y · Cited by 295
Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
Wooddell, C. I., Rozema, D. B., Hossbach, M., John, M., Hamilton, H. L., Chu, Q., Hegge, J. O., Klein, J. J., Wakefield, D. H., Oropeza, C. E., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.31 · Cited by 293
Self-citationActivity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†
Morrissey, D. V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J. A., Dickinson, B., McSwiggen, J. A., Vargeese, C., Bowman, K., Shaffer, C. S., et al. (2005) · Hepatology · doi:10.1002/hep.20702 · Cited by 290
Gao, S., Dagnaes-Hansen, F., Nielsen, E. J. B., Wengel, J., Besenbacher, F., Howard, K. A., & Kjems, J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.91 · Cited by 286
RNAi therapeutic and its innovative biotechnological evolution
Weng, Y., Xiao, H., Zhang, J., Liang, X.-J., & Huang, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.012 · Cited by 286
Curcio, C. A., Johnson, M., Huang, J.-D., & Rudolf, M. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.08.001 · Cited by 286
Chemical modification: the key to clinical application of RNA interference?
Corey, D. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33483 · Cited by 285
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
“Several ligands have been used to further increase hepatic accumulation and uptake, including lipids [181], steroids [182], tocopherol [183], and carbohydrates [184] (Figure 2).”
MethodOvercoming the Innate Immune Response to Small Interfering RNA
Judge, A., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 284
Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing Nanoparticles
Bartlett, D. W., & Davis, M. E. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0603539 · Cited by 283
RNAi‐based therapeutics–current status, challenges and prospects
Tiemann, K., & Rossi, J. J. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900023 · Cited by 283
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 282
RNAi Mechanisms and Applications
Kim, D. H., & Rossi, J. J. (2008) · BioTechniques · doi:10.2144/000112792 · Cited by 281
Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
Kanasty, R. L., Whitehead, K. A., Vegas, A. J., & Anderson, D. G. (2012) · Molecular Therapy · doi:10.1038/mt.2011.294 · Cited by 279
RNAi and small interfering RNAs in human disease therapeutic applications
Lares, M. R., Rossi, J. J., & Ouellet, D. L. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.07.009 · Cited by 277
Peer, D., Zhu, P., Carman, C. V., Lieberman, J., & Shimaoka, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608491104 · Cited by 275
A computational study of off-target effects of RNA interference
Qiu, S. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki324 · Cited by 274
RNAi Therapies: Drugging the Undruggable
Wu, S. Y., Lopez-Berestein, G., Calin, G. A., & Sood, A. K. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008362 · Cited by 273
Short hairpin RNA–expressing bacteria elicit RNA interference in mammals
Xiang, S., Fruehauf, J., & Li, C. J. (2006) · Nature Biotechnology · doi:10.1038/nbt1211 · Cited by 271
Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide
Schwarz, D. S., Ding, H., Kennington, L., Moore, J. T., Schelter, J., Burchard, J., Linsley, P. S., Aronin, N., Xu, Z., & Zamore, P. D. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020140 · Cited by 271
Advances in siRNA delivery in cancer therapy
Singh, A., Trivedi, P., & Jain, N. K. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2017.1307210 · Cited by 271
Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins
McNaughton, B. R., Cronican, J. J., Thompson, D. B., & Liu, D. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807883106 · Cited by 266
Huschka, R., Barhoumi, A., Liu, Q., Roth, J. A., Ji, L., & Halas, N. J. (2012) · ACS Nano · doi:10.1021/nn301135w · Cited by 264
Strategies to determine the biological function of microRNAs
Krützfeldt, J., Poy, M. N., & Stoffel, M. (2006) · Nature Genetics · doi:10.1038/ng1799 · Cited by 259
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
Gulino, A. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s23696 · Cited by 258
Tao, W., Yurdagul, A., Kong, N., Li, W., Wang, X., Doran, A. C., Feng, C., Wang, J., Islam, M. A., Farokhzad, O. C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1063 · Cited by 255
Geisbert, T. W., Hensley, L. E., Kagan, E., Yu, E. Z., Geisbert, J. B., Daddario‐DiCaprio, K., Fritz, E. A., Jahrling, P. B., McClintock, K., Phelps, J. R., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/504267 · Cited by 254
Nonviral methods for siRNA delivery
Gao, K., & Huang, L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800134q · Cited by 244
Advances in lipid nanoparticles for siRNA delivery
Tam, Y., Chen, S., & Cullis, P. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5030498 · Cited by 229
MicroRNA-based therapeutics in central nervous system injuries
Sun, P., Liu, D. Z., Jickling, G. C., Sharp, F. R., & Yin, K.-J. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18773871 · Cited by 228
Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C. D., Memari, F., Miri, S. R., Rezvani Rad, M., & Marmari, V. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200253 · Cited by 221
Abrams, M. T., Koser, M. L., Seitzer, J., Williams, S. C., DiPietro, M. A., Wang, W., Shaw, A. W., Mao, X., Jadhav, V., Davide, J. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.208 · Cited by 209
Xu, L., & Anchordoquy, T. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22243 · Cited by 209
Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo
Hassler, M. R., Turanov, A. A., Alterman, J. F., Haraszti, R. A., Coles, A. H., Osborn, M. F., Echeverria, D., Nikan, M., Salomon, W. E., Roux, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky037 · Cited by 181
Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?
Dowdy, S. F. (2023) · RNA · doi:10.1261/rna.079507.122 · Cited by 171
Lipid nanoparticles for short interfering RNA delivery
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158
Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain
Alterman, J. F., Hall, L. M., Coles, A. H., Hassler, M. R., Didiot, M.-C., Chase, K., Abraham, J., Sottosanti, E., Johnson, E., Sapp, E., et al. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.38 · Cited by 158
Improving siRNA Delivery In Vivo Through Lipid Conjugation
Osborn, M. F., & Khvorova, A. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0725 · Cited by 137
Visualization of self-delivering hydrophobically modified siRNA cellular internalization
Ly, S., Navaroli, D. M., Didiot, M.-C., Cardia, J., Pandarinathan, L., Alterman, J. F., Fogarty, K., Standley, C., Lifshitz, L. M., Bellve, K. D., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1005 · Cited by 132
Shi, B., Keough, E., Matter, A., Leander, K., Young, S., Carlini, E., Sachs, A. B., Tao, W., Abrams, M., Howell, B., et al. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411410885 · Cited by 125
“Human clinical trials using synthetic siRNA started in 2004 (Soutschek et al. 2004), and a list of ongoing clinical trials applying siRNA was summarized (Morin et al. 2009).”
BackgroundNew highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer
Yamato, K., Yamada, T., Kizaki, M., Ui-Tei, K., Natori, Y., Fujino, M., Nishihara, T., Ikeda, Y., Nasu, Y., Saigo, K., et al. (2008) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701118 · Cited by 110
Optimized Cholesterol-siRNA Chemistry Improves Productive Loading onto Extracellular Vesicles
Haraszti, R. A., Miller, R., Didiot, M.-C., Biscans, A., Alterman, J. F., Hassler, M. R., Roux, L., Echeverria, D., Sapp, E., DiFiglia, M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.024 · Cited by 107
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
“H) or even fully modified siRNAs have often created highly stable siRNA for applications in vivo (Soutschek et al., 2004; Allerson et al., 2005; Morrissey et al., 2005b; Zimmermann et al., 2006; Blidner et al., 2007; Nishina et al., 2008).”
BackgroundInfluentialNikan, M., Osborn, M. F., Coles, A. H., Godinho, B. M., Hall, L. M., Haraszti, R. A., Hassler, M. R., Echeverria, D., Aronin, N., & Khvorova, A. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.50 · Cited by 85
Landmesser, U., Haghikia, A., Leiter, L. A., Wright, R. S., Kallend, D., Wijngaard, P., Stoekenbroek, R., Kastelein, J. J., & Ray, K. K. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa077 · Cited by 83
Emerging Therapies in Transthyretin Amyloidosis – A New Wave of Hope After Years of Stagnancy?
Müller, M. L., Butler, J., & Heidecker, B. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1695 · Cited by 74
siRNA-lipid nanoparticles with long-term storage stability facilitate potent gene-silencing in vivo
Suzuki, Y., Hyodo, K., Tanaka, Y., & Ishihara, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.024 · Cited by 71
Metadata
- Authors
- Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R. K., Racie, T., Rajeev, K. G., Röhl, I., Toudjarska, I., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M., & Vornlocher, H.-P.
- Venue
- Nature
- Published
- 2004-11
- Volume
- 432
- Issue
- 7014
- Pages
- 173-178
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2116424844
- Cited by
- 2,183
- References
- 22
- FWCI
- 51.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.